Smith & Nephew plc (LON: SN)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 9.52B |
| Revenue (ttm) | 4.36B |
| Net Income (ttm) | 206.48M |
| Shares Out | 871.95M |
| EPS (ttm) | 0.24 |
| PE Ratio | 46.19 |
| Forward PE | 16.41 |
| Dividend | 0.29 (2.66%) |
| Ex-Dividend Date | Mar 28, 2024 |
| Volume | 165,308 |
| Open | 1,097.50 |
| Previous Close | 1,091.50 |
| Day's Range | n/a |
| 52-Week Range | 887.00 - 1,215.50 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 1, 2024 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other... [Read more]
Financial Performance
In 2023, Smith & Nephew's revenue was $5.55 billion, an increase of 6.40% compared to the previous year's $5.22 billion. Earnings were $263.00 million, an increase of 17.94%.
Financial numbers in USD Financial StatementsNews
Activist Cevian has a stake in Smith & Nephew. How it may help improve margins
British company Smith & Nephew is already a global leader in medical tech. Cevian could help it boost its profitability.
What's Driving Smith & Nephew PLC's Surprising 10% Stock Rally?
What's Driving Smith & Nephew PLC's Surprising 10% Stock Rally?
Activist Investor Takes Stake In Sports Medicine Player Smith & Nephew, Shares Surge
Shares of Smith & Nephew Plc SNN are trading higher on Friday. Smith+Nephew offers a medical technology portfolio across orthopedics, sports medicine, ENT, and advanced wound management.
Activist Investor Takes Stake In Sports Medicine Player Smith & Nephew, Shares Surge
Shares of Smith & Nephew Plc (NYSE: SNN) are trading higher on Friday. Smith+Nephew offers a medical technology portfolio across orthopedics, sports medicine, ENT, and advanced wound management. In a...
Smith & Nephew rises as activist investor Cevian takes stake
Activists should want reconstructive surgery at Smith & Nephew
A spinout of the medtech’s orthopaedics business would unlock value while shifting to the US could also deliver gains
Smith & Nephew shares jump as activist investor buys stake
Cevian has become the medical equipment firm’s second biggest shareholder after snapping up a 5% holding.
Smith & Nephew shares surge as activist Cevian Capital reveals 5% stake
Shares in Smith & Nephew increased 7% on Cevian’s disclosure that it had built up a 5% stake
London's FTSE 100 climbs on Smith & Nephew boost; UK polls underway
London's FTSE 100 climbed on Thursday, boosted by Smith & Nephew, while parliamentary polls in the country were underway, that the Labour Party looked set to win.
Activist investor Cevian takes stake in Smith & Nephew
Swedish group discloses stake in London-listed maker of medical devices
Smith & Nephew: Work To Be Done But Still Long-Term Potential
Smith & Nephew showed decent top line growth with a 6.4% increase in revenue last year. Read more to see why SNN stock is a Buy.
MIDAS SHARE TIPS: Why it soon won't be hip to give the cold shoulder to Smith & Nephew
S&N is far from perfect - but, overlooking the issues, the company is cheap and worth buying for short-term upside.
Smith & Nephew rocked as 43% of investors rebel over fat cat pay
In what amounted to a bloody nose for the FTSE 100 firm, 43% of investors voted against raising Deepak Nath's maximum earnings to £9.4m.
Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript
Nearly half of Smith & Nephew investors revolt against chief executive pay increase
Medical device manufacturer’s policy ultimately passed, making maximum payout for Deepak Nath $11.8m Nils Pratley: The boardroom pay game has changed for ever Smith & Nephew had a shareholder revolt o...
At 3-0 to the Brilos, the boardroom pay game has changed forever | Nils Pratley
As Smith & Nephew is ‘British in listing only’ investors have been persuaded the CEO should be remunerated accordingly Our performance has been so bad that we must pay our executives more. If this cor...
BUSINESS CLOSE: GSK raises guidance; Next exceeds forecasts; Aston Martin losses nearly double
Among the companies with reports and trading updates today are Next, GSK, Aston Martin Lagonda, Haleon, CVS Group, Smith & Nephew and Computacenter.
UK's Smith+Nephew retains annual forecasts despite Q1 revenue miss
British medical equipment maker Smith+Nephew retained its annual revenue and profit forecasts on Wednesday, despite marginally missing market expectations for first-quarter revenue due to a softness i...
Three Quick Facts: Computacenter, Next, Smith & Nephew
Tony Cross picks three things to know about the markets, featuring Computacenter, Next, Smith & Nephew
Smith & Nephew investors urged to oppose ‘excessive’ pay rise for boss
FTSE 100 group wants to raise US-based Deepak Nath’s pay by almost 30% to a maximum of $11.8mn
Smith+Nephew signs exclusive distribution agreement to provide unique NAVBIT SPRINT™ solution in Australia
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, anno...
Smith+Nephew's PICO™ Single Use Negative Pressure Wound Therapy System provides better clinical outcomes versus standard of care according to UK National Institute for Health and Care Excellence (NICE)
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE)...
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce the launch of its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US as a patient-centr...
Smith & Nephew goes ex dividend Monday
Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world's premier mixed martial ar...